chr1-11949898-C-T

Variant summary

Our verdict is Benign. The variant received -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BA1

The NM_000302.4(PLOD1):​c.294C>T​(p.Phe98Phe) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.311 in 1,613,408 control chromosomes in the GnomAD database, including 82,689 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.25 ( 6299 hom., cov: 32)
Exomes 𝑓: 0.32 ( 76390 hom. )

Consequence

PLOD1
NM_000302.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:12

Conservation

PhyloP100: 1.08

Publications

27 publications found
Variant links:
Genes affected
PLOD1 (HGNC:9081): (procollagen-lysine,2-oxoglutarate 5-dioxygenase 1) Lysyl hydroxylase is a membrane-bound homodimeric protein localized to the cisternae of the endoplasmic reticulum. The enzyme (cofactors iron and ascorbate) catalyzes the hydroxylation of lysyl residues in collagen-like peptides. The resultant hydroxylysyl groups are attachment sites for carbohydrates in collagen and thus are critical for the stability of intermolecular crosslinks. Some patients with Ehlers-Danlos syndrome type VI have deficiencies in lysyl hydroxylase activity. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]
PLOD1 Gene-Disease associations (from GenCC):
  • Ehlers-Danlos syndrome, kyphoscoliotic type 1
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Orphanet, PanelApp Australia, G2P

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -19 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.41).
BP6
Variant 1-11949898-C-T is Benign according to our data. Variant chr1-11949898-C-T is described in ClinVar as Benign. ClinVar VariationId is 255803.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=1.08 with no splicing effect.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.415 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PLOD1NM_000302.4 linkc.294C>T p.Phe98Phe synonymous_variant Exon 3 of 19 ENST00000196061.5 NP_000293.2
PLOD1NM_001316320.2 linkc.435C>T p.Phe145Phe synonymous_variant Exon 4 of 20 NP_001303249.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PLOD1ENST00000196061.5 linkc.294C>T p.Phe98Phe synonymous_variant Exon 3 of 19 1 NM_000302.4 ENSP00000196061.4

Frequencies

GnomAD3 genomes
AF:
0.254
AC:
38595
AN:
151958
Hom.:
6298
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0637
Gnomad AMI
AF:
0.138
Gnomad AMR
AF:
0.289
Gnomad ASJ
AF:
0.215
Gnomad EAS
AF:
0.378
Gnomad SAS
AF:
0.432
Gnomad FIN
AF:
0.437
Gnomad MID
AF:
0.253
Gnomad NFE
AF:
0.315
Gnomad OTH
AF:
0.274
GnomAD2 exomes
AF:
0.329
AC:
82814
AN:
251354
AF XY:
0.336
show subpopulations
Gnomad AFR exome
AF:
0.0589
Gnomad AMR exome
AF:
0.352
Gnomad ASJ exome
AF:
0.220
Gnomad EAS exome
AF:
0.375
Gnomad FIN exome
AF:
0.446
Gnomad NFE exome
AF:
0.316
Gnomad OTH exome
AF:
0.331
GnomAD4 exome
AF:
0.317
AC:
463265
AN:
1461332
Hom.:
76390
Cov.:
36
AF XY:
0.321
AC XY:
233607
AN XY:
726970
show subpopulations
African (AFR)
AF:
0.0541
AC:
1812
AN:
33476
American (AMR)
AF:
0.351
AC:
15692
AN:
44716
Ashkenazi Jewish (ASJ)
AF:
0.220
AC:
5760
AN:
26134
East Asian (EAS)
AF:
0.343
AC:
13604
AN:
39698
South Asian (SAS)
AF:
0.428
AC:
36914
AN:
86248
European-Finnish (FIN)
AF:
0.446
AC:
23806
AN:
53394
Middle Eastern (MID)
AF:
0.310
AC:
1787
AN:
5766
European-Non Finnish (NFE)
AF:
0.311
AC:
345222
AN:
1111516
Other (OTH)
AF:
0.309
AC:
18668
AN:
60384
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.482
Heterozygous variant carriers
0
16854
33708
50562
67416
84270
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
11198
22396
33594
44792
55990
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.254
AC:
38608
AN:
152076
Hom.:
6299
Cov.:
32
AF XY:
0.262
AC XY:
19467
AN XY:
74308
show subpopulations
African (AFR)
AF:
0.0635
AC:
2637
AN:
41542
American (AMR)
AF:
0.289
AC:
4418
AN:
15264
Ashkenazi Jewish (ASJ)
AF:
0.215
AC:
747
AN:
3472
East Asian (EAS)
AF:
0.378
AC:
1947
AN:
5154
South Asian (SAS)
AF:
0.431
AC:
2075
AN:
4818
European-Finnish (FIN)
AF:
0.437
AC:
4605
AN:
10544
Middle Eastern (MID)
AF:
0.262
AC:
77
AN:
294
European-Non Finnish (NFE)
AF:
0.315
AC:
21391
AN:
67964
Other (OTH)
AF:
0.277
AC:
585
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1372
2743
4115
5486
6858
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
414
828
1242
1656
2070
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.289
Hom.:
12124
Bravo
AF:
0.231
Asia WGS
AF:
0.390
AC:
1354
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:12
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:6
Apr 04, 2023
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Sep 29, 2016
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 09, 2025
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Genome Diagnostics Laboratory, Amsterdam University Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Ehlers-Danlos syndrome, kyphoscoliotic type 1 Benign:4
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Oct 25, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jul 30, 2020
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Familial thoracic aortic aneurysm and aortic dissection Benign:1
Jan 23, 2015
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

not provided Benign:1
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.41
CADD
Benign
13
DANN
Benign
0.82
PhyloP100
1.1
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs7529452; hg19: chr1-12009955; COSMIC: COSV52144592; COSMIC: COSV52144592; API